C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
C4X Discovery Holdings plc has licenced its oral C4XD oral IL-17A inhibitor programme to Sanofi.
Increasing the efficiency of bioprocess workflows is key to stay competitive. The SciVario twin helps to develop and optimize processes in terms of time and cost efficiency. All critical process parameters can be precisely controlled directly at the controller’s touch screen. Regardless of the research segment, it is suitable for microbial and cell culture applications. The innovative bay-drawer system enables the system to flexibly adapt to unique requirements and changing processes. Eppendorf will offer updates with new functional modules, support for more, larger bioreactors, and additional software features to make the SciVario twin a future-proof solution.
Intravacc has announced positive data for its nasal SARS-CoV-2 vaccine that embeds the viral spike antigen in bacterial Outer Membrane Vesicles (OMV)
In a new statement, the EU regulatory authority EMA postulates that AstraZeneca’s vaccine causes serious deep vein thrombosis.